Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this program is to evaluate the safety, tolerability, and efficacy of the new concomitant and sequential temozolomide regimen in newly diagnosed Glioblastoma patients in a routine care setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Dacarbazine; Temozolomide

Criteria

Inclusion Criteria:

• Newly diagnosed Glioblastoma multiforme

Exclusion Criteria:

• History of hypersensitivity to temozolomide or its components, or to dacarbazine.

• Women who are pregnant or breast-feeding.

• Patients with severe myelosuppression.